Inovio Pharmaceuticals (INO) to Release Quarterly Earnings on Monday

Inovio Pharmaceuticals (NASDAQ:INOGet Free Report) is set to issue its quarterly earnings data after the market closes on Monday, May 13th. Analysts expect the company to announce earnings of ($1.08) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Inovio Pharmaceuticals Stock Down 4.7 %

Shares of Inovio Pharmaceuticals stock opened at $10.65 on Friday. The firm’s 50 day moving average price is $11.23 and its 200-day moving average price is $37.85. Inovio Pharmaceuticals has a 52-week low of $3.89 and a 52-week high of $14.75.

Analyst Upgrades and Downgrades

INO has been the topic of a number of analyst reports. Oppenheimer raised shares of Inovio Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $48.00 price objective on the stock in a research report on Thursday, January 25th. StockNews.com downgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, April 5th. Finally, Royal Bank of Canada reissued a “sector perform” rating on shares of Inovio Pharmaceuticals in a research report on Thursday, March 7th.

Read Our Latest Analysis on Inovio Pharmaceuticals

About Inovio Pharmaceuticals

(Get Free Report)

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.

See Also

Earnings History for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.